What is a stock summary page? Click here for an overview.
Business Description
Egetis Therapeutics AB
ISIN : SE0003815604
Compare
Compare
Traded in other countries / regions
EGTX.Sweden0ABW.UKP0F.Germany IPO Date
2023-01-27Description
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.07 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.23 | |||||
| Debt-to-EBITDA | -0.36 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.22 | |||||
| Beneish M-Score | -3.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.4 | |||||
| 3-Year EBITDA Growth Rate | -21.7 | |||||
| 3-Year EPS without NRI Growth Rate | -22 | |||||
| 3-Year FCF Growth Rate | -0.4 | |||||
| 3-Year Book Growth Rate | -22.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 207.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.28 | |||||
| 9-Day RSI | 25.76 | |||||
| 14-Day RSI | 23.41 | |||||
| 3-1 Month Momentum % | -27.84 | |||||
| 6-1 Month Momentum % | -9.45 | |||||
| 12-1 Month Momentum % | -24.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | |||||
| Quick Ratio | 1.86 | |||||
| Cash Ratio | 1.72 | |||||
| Days Inventory | 23.28 | |||||
| Days Sales Outstanding | 176.65 | |||||
| Days Payable | 770.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.9 | |||||
| Shareholder Yield % | -22.88 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.89 | |||||
| Operating Margin % | -712.77 | |||||
| Net Margin % | -743.72 | |||||
| FCF Margin % | -493.29 | |||||
| ROE % | -77 | |||||
| ROA % | -49.42 | |||||
| ROIC % | -61.46 | |||||
| 3-Year ROIIC % | -161 | |||||
| ROC (Joel Greenblatt) % | -8968.93 | |||||
| ROCE % | -57.95 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 39.6 | |||||
| PS Ratio | 25.22 | |||||
| PB Ratio | 2.76 | |||||
| Price-to-Tangible-Book | 16 | |||||
| EV-to-EBIT | -3.76 | |||||
| EV-to-Forward-EBIT | 5.77 | |||||
| EV-to-EBITDA | -3.76 | |||||
| EV-to-Forward-EBITDA | 5.77 | |||||
| EV-to-Revenue | 25.87 | |||||
| EV-to-Forward-Revenue | 2.52 | |||||
| EV-to-FCF | -4.71 | |||||
| Price-to-GF-Value | 0.8 | |||||
| Price-to-Net-Current-Asset-Value | 17.45 | |||||
| Price-to-Net-Cash | 27.43 | |||||
| Earnings Yield (Greenblatt) % | -26.61 | |||||
| FCF Yield % | -15.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Egetis Therapeutics AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 46.2 | ||
| EPS (TTM) (kr) | -1.1 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 87.32 | ||
| 14-Day RSI | 23.41 | ||
| 14-Day ATR (kr) | 0.108612 | ||
| 20-Day SMA (kr) | 4.52825 | ||
| 12-1 Month Momentum % | -24.07 | ||
| 52-Week Range (kr) | 3.6 - 9.28 | ||
| Shares Outstanding (Mil) | 359.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Egetis Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Egetis Therapeutics AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Egetis Therapeutics AB Frequently Asked Questions
What is Egetis Therapeutics AB(LTS:0ABW)'s stock price today?
The current price of LTS:0ABW is kr3.84. The 52 week high of LTS:0ABW is kr9.28 and 52 week low is kr3.60.
When is next earnings date of Egetis Therapeutics AB(LTS:0ABW)?
The next earnings date of Egetis Therapeutics AB(LTS:0ABW) is 2025-04-30.
Does Egetis Therapeutics AB(LTS:0ABW) pay dividends? If so, how much?
Egetis Therapeutics AB(LTS:0ABW) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers